$CGIX went public in April at $10 and hits $22 almost 6mo later. Focused on DNA probes for cancer diagnostics and drug/treatment monitoring. Backing by the "Buffet" of biotech John PappaJohn, strong received buy rating from Aegis w/ $25 target, pharma partnerships expand. (Disclosure: am early holder and long)
Your smartphone now can see what the naked eye cannot: A single virus and bits of material less than one-thousandth of the width of a human hair.
- ▼ 2013 (23)
- ► 2008 (24)
- ► 2007 (65)
- ► 2006 (77)